Innovation in bone healing and tissue repair

Key Publications

Cunningham BW, Schense J, Murgatroyd AA, McAfee PC.
An Investigational Study of a Novel Parathyroid Hormone Based Bone Graft Substitute for Interbody Spinal Fusion: An In Vivo Ovine Mode.
Podium Presentation. North American Spine Society Annual Meeting, San Francisco, Oct. 2015 Lyon T, Garcia FB, Bohatyrewciz A, Casa de Pantoja V, Detre Z, Dresing K, Dubrana F, Giannoudis P, Gorecki A, Gunther T, Harries T, Hax PM, Krettek C, Kwiatkowski K, Vence ML, Magyari Z, Mathevon H, Messmer P, Mohanty K, Montanez E, Pace A, Patel A, Piltz S, Pohl A, Rando A, Raschke M, Roussignol X, Horst S, Varga E, Widuchowski J, Zagh I, Schense J.
A novel PTH based bone graft substitute demonstrates non-inferiority to autograft in a large phase IIb study of Tibial Plateau Fractures.
Podium Presentation. Orthopedic and Trauma Association Annual Meeting, San Diego, Oct. 2015 Schense J, von Rechenberg B, Stauber M, Ferguson S.
Novel PTH based Bone Graft Substitute for treatment of fractures – results from a large ovine Tibial Plateau Defects study
Podium Presentation. Orthopedic and Trauma Association Annual Meeting, San Diego, Oct. 2015 Mueller TL, Wirth AJ, van Lenthe GH, Goldhahn J, Schense J, Jamieson V, Messmer P, Uebelhart D, Weishaupt D, Egermann M, Müller R.
Mechanical stability in a human radius fracture treated with a novel tissue-engineered bone substitute: a non-invasive, longitudinal assessment using high-resolution pQCT in combination with finite element analysis.
J Tissue Eng Regen Med. 2011 May;5(5):415-20. Arrighi I, Mark S, Alvisi M, von Rechenberg B, Hubbell JA, Schense JC.
Bone healing induced by local delivery of an engineered parathyroid hormone prodrug.
Biomaterials. 2009 Mar;30(9):1763-71. Wechsler S, Fehr D, Molenberg A, Raeber G, Schense JC, Weber FE.
A novel, tissue occlusive poly(ethylene glycol) hydrogel material.
J Biomed Mater Res A. 2008 May;85(2):285-92. Fuerst A, Derungs S, von Rechenberg B, Auer JA, Schense J, Watson J.
Use of a parathyroid hormone peptide (PTH(1-34))-enriched fibrin hydrogel for the treatment of a subchondral cystic lesion in the proximal interphalangeal joint of a warmblood filly.
J Vet Med A Physiol Pathol Clin Med. 2007 Mar;54(2):107-12.

Additional Publications on Fibrin-based technologies

Mittermayr R, Slezak P, Haffner N, Smolen D, Hartinger J, Hofmann A, Schense J, Spazierer D, Gampfer J, Goppelt A, Redl H.
Controlled release of fibrin matrix-conjugated platelet derived growth factor improves ischemic tissue regeneration by functional angiogenesis.
Acta Biomater. 2015 Oct 20. pii: S1742-7061(15)30158-6. Mittermayr R, Branski L, Moritz M, Jeschke MG, Herndon DN, Traber D, Schense J, Gampfer J, Goppelt A, Redl H.
Fibrin biomatrix-conjugated platelet-derived growth factor AB accelerates wound healing in severe thermal injury.
J Tissue Eng Regen Med. 2013 May 31.
Reduction in postlaminectomy epidural adhesions in sheep using a fibrin sealant-based medicated adhesion barrier.
Richards PJ, Turner AS, Gisler SM, Kraft S, Nuss K, Mark S, Seim HB 3rd, Schense J. J Biomed Mater Res B Appl Biomater. 2010 Feb;92(2):439-46
Bone Healing Induced by Local Delivery of A PTH1-34 Fusion Peptide
Orthopedic Research Society Annual Meeting 2007 Mark S, Schense J; Watson J, Arrighi I, Hubbell JA, Andrianaly NH, von Rechenberg B.
Enhancement of Bone Healing by Locally Delivered Parathyroid Hormone Fusion Peptide in a Diaphyseal Defect in the Sheep Tibia
Orthopedic Research Society Annual Meeting 2007 Dragieva G, Jen A, Bavand M, Hubbell JA, Fetz D, Burg G, Hafner J.
Treating venous ulcers with variant PDGF covalently bound in fibrin gel
2nd WUWHS Meeting, July 8-13 Paris, 2004. Hall H, Baechi T, Hubbell JA.
Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro.
Microvasc Res. 2001 Nov;62(3):315-26. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA.
Covalently conjugated VEGF--fibrin matrices for endothelialization.
J Control Release. 2001 May 14;72(1-3):101-13. Sakiyama-Elbert SE, Panitch A, Hubbell JA.
Development of growth factor fusion proteins for cell-triggered drug delivery.
FASEB J. 2001 May;15(7):1300-2. Sakiyama-Elbert SE, Hubbell JA.
Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix.
J Control Release. 2000 Oct 3;69(1):149-58. Schense JC, Bloch J, Aebischer P, Hubbell JA.
Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension.
Nat Biotechnol. 2000 Apr;18(4):415-9. Sakiyama-Elbert SE, Hubbell JA.
Development of fibrin derivatives for controlled release of heparin-binding growth factors.
J Control Release. 2000 Apr 3;65(3):389-402. Sakiyama SE, Schense JC, Hubbell JA.
Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering.
FASEB J. 1999 Dec;13(15):2214-24. Schense JC, Hubbell JA.
Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa.
Bioconjug Chem. 1999 Jan-Feb;10(1):75-81. Herbert CB, Nagaswami C, Bittner GD, Hubbell JA, Weisel JW.
Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels.
J Biomed Mater Res. 1998 Jun 15;40(4):551-9. Herbert CB, Bittner GD, Hubbell JA.
Effects of fibinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels.
J Comp Neurol. 1996 Feb 12;365(3):380-91.

Additional Publications on Synthetic-based technologies

Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmokel H, Bezuidenhout D, Djonov V, Zilla P, Hubbell JA.
Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth.
Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmokel H, Bezuidenhout D, Djonov V, Zilla P, Hubbell JA. Lutolf MP, Hubbell JA.
Synthesis and physicochemical characterization of end-linked poly (ethylene glycol)-co-peptide hydrogels formed by Michael-type addition.
Biomacromolecules. 2003 May-Jun;4(3):713-22. tolf MP, Weber FE, Schmoekel HG, Schense JC, Kohler T, Muller R, Hubbell JA.
Repair of bone defects using synthetic mimetics of collagenous extracellular matrices.
Nat Biotechnol. 2003 May;21(5):513-8. Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, Fields GB, Hubbell JA.
Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics.
  Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5413-8. Vernon B, Tirelli N, Bachi T, Haldimann D, Hubbell JA.
Water-borne, in situ crosslinked biomaterials from phase-segregated precursors.
  J Biomed Mater Res. 2003 Mar 1;64A(3):447-56. Elbert DL, Hubbell JA.
Conjugate addition reactions combined with free-radical cross-linking for the design of materials for tissue engineering.
Biomacromolecules. 2001 Summer;2(2):430-41. Lutolf MP, Tirelli N, Cerritelli S, Cavalli L, Hubbell JA.
Systematic modulation of Michael-type reactivity of thiols through the use of charged amino acids.
Bioconjug Chem. 2001 Nov-Dec;12(6):1051-6. Elbert DL, Pratt AB, Lutolf MP, Halstenberg S, Hubbell JA.
Protein delivery from materials formed by self-selective conjugate addition reactions.
J Control Release. 2001 Sep 11;76(1-2):11-25. Schense JC, Hubbell JA.
Three-dimensional migration of neurites is mediated by adhesion site density and affinity.
J Biol Chem. 2000 Mar 10;275(10):6813-8.

Publications on CYT003 technology

Casale TB, Cole J, Beck E, Vogelmeier CF, Willers J, Lassen C, Hammann-
Haenni A, Trokan L, Saudan P, Wechsler ME. CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study.
Allergy. 70(9):1160-8. 2015 Beeh, KM, Kanniess, F, Wagner, F, Schilder, C, Naudts, I, Hammann-Haenni, A, Willers, J, Stocker, H, Mueller, P, Bachmann, MF, Renner.
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma
J Allergy Clin Immunol, Vol. 131 (3) pp 866-874, 2013 Klimek, L, Willers, J, Hammann-Haenni, A, Pfaar, O, Stocker, H, Mueller, P, Renner, WA, Bachmann,
MF Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
Clin Exp Allergy, Vol. 41(9) pp. 1305-1312, 2011 Senti, G, Johansen, P, Haug, S, Bull, C, Gottschaller, C, Müller, P, Pfister, T, Maurer, P, Bachmann, MF, Graf, N, Kündig,
TM Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Clin Exp Allergy, Vol. 39(4) pp. 562-570, 2009 Manolova, V, Flace, A, Bauer, M, Schwarz, K, Saudan, P, Bachmann, MF
Nanoparticles target distinct dendritic cell populations according to their size.
Eur J Immunol, Vol. 38(5) pp. 1404-1413, 2008

Publications on VLP technology

Low JG, Lee LS, Ooi EE, Ethirajulu K, Yeo P, Matter A, Connolly JE, Skibinski DA, Saudan P, Bachmann M, Hanson BJ, Lu Q, Maurer-Stroh S, Lim S, Novotny-Diermayr V.
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
Vaccine, 32(39):5041-8, 2014 Jegerlehner, A, Zabel, F, Langer, A, Dietmeier, K, Jennings, GT, Saudan, P, Bachmann, MF
Bacterially produced recombinant influenza vaccines based on virus-like particles.
PLoS One, Vol. 8(11) pp. e78947, 2013 Skibinski, DA, Hanson, BJ, Lin, Y, von Messling, V, Jegerlehner, A, Tee, JB, Chye, de H, Wong, SK, Ng, AA, Lee, HY, Au, B, Lee, BT, Santoso, L, Poidinger, M, Fairhurst, AM, Matter, A, Bachmann, MF, Saudan, P, Connolly,
JE Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine.
PLoS One, Vol. 8(10) pp. e76571, 2013 Saudan, P, Bachmann,
MF Noninfectious disease vaccines.
Vaccines 6th Ed., Plotkin, SA, Orenstein, W and Offit, PA (Eds.) Chapter 54, 2012 Schmitz, N, Beerli, RR, Bauer, M, Jegerlehner, A, Dietmeier, K, Maudrich, M, Pumpens, P, Saudan, P, Bachmann, MF.
Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection.
Eur J Immunol, Vol. 42(4) pp. 863-9, 2012 Wiessner, C, Wiederhold, KH, Tissot, AC, Frey, P, Danner, S, Jacobson, LH, Jennings, GT, Lüönd, R, Ortmann, R, Reichwald, J, Zurini, M, Mir, A, Bachmann, MF, Staufenbiel, M
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.
J Neurosci, Vol. 31(25) pp. 9323-31, 2011 Bachmann, MF, Jennings, GT.
Therapeutic vaccines for chronic diseases: successes and technical challenges.
Philos Trans R Soc Lond B Biol Sci, Vol. 366(1579) pp. 2815-22, 2011. Bachmann, MF, Jennings, GT.
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.
Nat Rev Immunol, Vol. 10(11) pp. 787-96, 2010 Zou, Y, Sonderegger, I, Lipowsky, G, Jennings, GT, Schmitz, N, Landi, M, Kopf, M, Bachmann, MF
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice.
Vaccine, Vol. 28(18) pp. 3192-200, 2010 Link, A, Bachmann, MF.
Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.
Immunotherapy, Vol. 2(4) pp. 561-74, 2010 Jennings, GT, Bachmann, MF
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases.
Annu Rev Pharmacol Toxicol, Vol. 49 pp. 303-26, 2009 Schmitz, N, Dietmeier, K, Bauer, M, Maudrich, M, Utzinger, S, Muntwiler, S, Saudan, P, Bachmann, MF
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.
J Exp Med, Vol. 206(9) pp.1941-55, 2009 Tissot, AC, Maurer, P, Nussberger, J, Sabat, R, Pfister, T, Ignatenko, S, Volk, HD, Stocker, H, Müller, P, Jennings, GT, Wagner, F, Bachmann, MF
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
Lancet, Vol. 371(9615) pp. 821-7, 2008 Jennings, GT, Bachmann, MF.
The coming of age of virus-like particle vaccines.
 Vol. 389(5) pp. 521-36, 2008 Spohn, G, Keller, I, Beck, M, Grest, P, Jennings, GT, Bachmann, MF
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis.
Eur J Immunol, Vol. 38(3) pp. 877-87, 2008 Maurer, P, Bachmann, MF
Vaccination against nicotine: an emerging therapy for tobacco dependence.
Expert Opin Investig Drugs, Vol. 16(11) pp. 1775-83, 2007 Sonderegger, I, Röhn, TA, Kurrer, MO, Iezzi, G, Zou, Y, Kastelein, RA, Bachmann, MF, Kopf, M
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.
Eur J Immunol, Vol. 36(11) pp. 2849-56, 2006 Röhn, TA, Jennings, GT, Hernandez, M, Grest, P, Beck, M, Zou, Y, Kopf, M, Bachmann, MF
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.
Eur J Immunol, Vol. 36(11) pp. 2857-67, 2006
Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Publications

Key Publications

Cunningham BW, Schense J, Murgatroyd AA, McAfee PC.
An Investigational Study of a Novel Parathyroid Hormone Based Bone Graft Substitute for Interbody Spinal Fusion: An In Vivo Ovine Mode.
Podium Presentation. North American Spine Society Annual Meeting, San Francisco, Oct. 2015 Lyon T, Garcia FB, Bohatyrewciz A, Casa de Pantoja V, Detre Z, Dresing K, Dubrana F, Giannoudis P, Gorecki A, Gunther T, Harries T, Hax PM, Krettek C, Kwiatkowski K, Vence ML, Magyari Z, Mathevon H, Messmer P, Mohanty K, Montanez E, Pace A, Patel A, Piltz S, Pohl A, Rando A, Raschke M, Roussignol X, Horst S, Varga E, Widuchowski J, Zagh I, Schense J.
A novel PTH based bone graft substitute demonstrates non-inferiority to autograft in a large phase IIb study of Tibial Plateau Fractures.
Podium Presentation. Orthopedic and Trauma Association Annual Meeting, San Diego, Oct. 2015 Schense J, von Rechenberg B, Stauber M, Ferguson S.
Novel PTH based Bone Graft Substitute for treatment of fractures – results from a large ovine Tibial Plateau Defects study
Podium Presentation. Orthopedic and Trauma Association Annual Meeting, San Diego, Oct. 2015 Mueller TL, Wirth AJ, van Lenthe GH, Goldhahn J, Schense J, Jamieson V, Messmer P, Uebelhart D, Weishaupt D, Egermann M, Müller R.
Mechanical stability in a human radius fracture treated with a novel tissue-engineered bone substitute: a non-invasive, longitudinal assessment using high-resolution pQCT in combination with finite element analysis.
J Tissue Eng Regen Med. 2011 May;5(5):415-20. Arrighi I, Mark S, Alvisi M, von Rechenberg B, Hubbell JA, Schense JC.
Bone healing induced by local delivery of an engineered parathyroid hormone prodrug.
Biomaterials. 2009 Mar;30(9):1763-71. Wechsler S, Fehr D, Molenberg A, Raeber G, Schense JC, Weber FE.
A novel, tissue occlusive poly(ethylene glycol) hydrogel material.
J Biomed Mater Res A. 2008 May;85(2):285-92. Fuerst A, Derungs S, von Rechenberg B, Auer JA, Schense J, Watson J.
Use of a parathyroid hormone peptide (PTH(1-34))-enriched fibrin hydrogel for the treatment of a subchondral cystic lesion in the proximal interphalangeal joint of a warmblood filly.
J Vet Med A Physiol Pathol Clin Med. 2007 Mar;54(2):107-12.

Additional Publications on Fibrin-based technologies

Mittermayr R, Slezak P, Haffner N, Smolen D, Hartinger J, Hofmann A, Schense J, Spazierer D, Gampfer J, Goppelt A, Redl H.
Controlled release of fibrin matrix-conjugated platelet derived growth factor improves ischemic tissue regeneration by functional angiogenesis.
Acta Biomater. 2015 Oct 20. pii: S1742-7061(15)30158-6. Mittermayr R, Branski L, Moritz M, Jeschke MG, Herndon DN, Traber D, Schense J, Gampfer J, Goppelt A, Redl H.
Fibrin biomatrix-conjugated platelet-derived growth factor AB accelerates wound healing in severe thermal injury.
J Tissue Eng Regen Med. 2013 May 31.
Reduction in postlaminectomy epidural adhesions in sheep using a fibrin sealant-based medicated adhesion barrier.
Richards PJ, Turner AS, Gisler SM, Kraft S, Nuss K, Mark S, Seim HB 3rd, Schense J. J Biomed Mater Res B Appl Biomater. 2010 Feb;92(2):439-46
Bone Healing Induced by Local Delivery of A PTH1-34 Fusion Peptide
Orthopedic Research Society Annual Meeting 2007 Mark S, Schense J; Watson J, Arrighi I, Hubbell JA, Andrianaly NH, von Rechenberg B.
Enhancement of Bone Healing by Locally Delivered Parathyroid Hormone Fusion Peptide in a Diaphyseal Defect in the Sheep Tibia
Orthopedic Research Society Annual Meeting 2007 Dragieva G, Jen A, Bavand M, Hubbell JA, Fetz D, Burg G, Hafner J.
Treating venous ulcers with variant PDGF covalently bound in fibrin gel
2nd WUWHS Meeting, July 8-13 Paris, 2004. Hall H, Baechi T, Hubbell JA.
Molecular properties of fibrin-based matrices for promotion of angiogenesis in vitro.
Microvasc Res. 2001 Nov;62(3):315-26. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA.
Covalently conjugated VEGF--fibrin matrices for endothelialization.
J Control Release. 2001 May 14;72(1-3):101-13. Sakiyama-Elbert SE, Panitch A, Hubbell JA.
Development of growth factor fusion proteins for cell-triggered drug delivery.
FASEB J. 2001 May;15(7):1300-2. Sakiyama-Elbert SE, Hubbell JA.
Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix.
J Control Release. 2000 Oct 3;69(1):149-58. Schense JC, Bloch J, Aebischer P, Hubbell JA.
Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension.
Nat Biotechnol. 2000 Apr;18(4):415-9. Sakiyama-Elbert SE, Hubbell JA.
Development of fibrin derivatives for controlled release of heparin-binding growth factors.
J Control Release. 2000 Apr 3;65(3):389-402. Sakiyama SE, Schense JC, Hubbell JA.
Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering.
FASEB J. 1999 Dec;13(15):2214-24. Schense JC, Hubbell JA.
Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa.
Bioconjug Chem. 1999 Jan-Feb;10(1):75-81. Herbert CB, Nagaswami C, Bittner GD, Hubbell JA, Weisel JW.
Effects of fibrin micromorphology on neurite growth from dorsal root ganglia cultured in three-dimensional fibrin gels.
J Biomed Mater Res. 1998 Jun 15;40(4):551-9. Herbert CB, Bittner GD, Hubbell JA.
Effects of fibinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels.
J Comp Neurol. 1996 Feb 12;365(3):380-91.

Additional Publications on Synthetic-based technologies

Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmokel H, Bezuidenhout D, Djonov V, Zilla P, Hubbell JA.
Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth.
Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmokel H, Bezuidenhout D, Djonov V, Zilla P, Hubbell JA. Lutolf MP, Hubbell JA.
Synthesis and physicochemical characterization of end-linked poly (ethylene glycol)-co-peptide hydrogels formed by Michael-type addition.
Biomacromolecules. 2003 May-Jun;4(3):713-22. tolf MP, Weber FE, Schmoekel HG, Schense JC, Kohler T, Muller R, Hubbell JA.
Repair of bone defects using synthetic mimetics of collagenous extracellular matrices.
Nat Biotechnol. 2003 May;21(5):513-8. Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, Fields GB, Hubbell JA.
Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics.
  Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5413-8. Vernon B, Tirelli N, Bachi T, Haldimann D, Hubbell JA.
Water-borne, in situ crosslinked biomaterials from phase-segregated precursors.
  J Biomed Mater Res. 2003 Mar 1;64A(3):447-56. Elbert DL, Hubbell JA.
Conjugate addition reactions combined with free-radical cross-linking for the design of materials for tissue engineering.
Biomacromolecules. 2001 Summer;2(2):430-41. Lutolf MP, Tirelli N, Cerritelli S, Cavalli L, Hubbell JA.
Systematic modulation of Michael-type reactivity of thiols through the use of charged amino acids.
Bioconjug Chem. 2001 Nov-Dec;12(6):1051-6. Elbert DL, Pratt AB, Lutolf MP, Halstenberg S, Hubbell JA.
Protein delivery from materials formed by self-selective conjugate addition reactions.
J Control Release. 2001 Sep 11;76(1-2):11-25. Schense JC, Hubbell JA.
Three-dimensional migration of neurites is mediated by adhesion site density and affinity.
J Biol Chem. 2000 Mar 10;275(10):6813-8.

Publications on CYT003 technology

Casale TB, Cole J, Beck E, Vogelmeier CF, Willers J, Lassen C, Hammann-
Haenni A, Trokan L, Saudan P, Wechsler ME. CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study.
Allergy. 70(9):1160-8. 2015 Beeh, KM, Kanniess, F, Wagner, F, Schilder, C, Naudts, I, Hammann-Haenni, A, Willers, J, Stocker, H, Mueller, P, Bachmann, MF, Renner.
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma
J Allergy Clin Immunol, Vol. 131 (3) pp 866-874, 2013 Klimek, L, Willers, J, Hammann-Haenni, A, Pfaar, O, Stocker, H, Mueller, P, Renner, WA, Bachmann,
MF Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
Clin Exp Allergy, Vol. 41(9) pp. 1305-1312, 2011 Senti, G, Johansen, P, Haug, S, Bull, C, Gottschaller, C, Müller, P, Pfister, T, Maurer, P, Bachmann, MF, Graf, N, Kündig,
TM Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Clin Exp Allergy, Vol. 39(4) pp. 562-570, 2009 Manolova, V, Flace, A, Bauer, M, Schwarz, K, Saudan, P, Bachmann, MF
Nanoparticles target distinct dendritic cell populations according to their size.
Eur J Immunol, Vol. 38(5) pp. 1404-1413, 2008

Publications on VLP technology

Low JG, Lee LS, Ooi EE, Ethirajulu K, Yeo P, Matter A, Connolly JE, Skibinski DA, Saudan P, Bachmann M, Hanson BJ, Lu Q, Maurer-Stroh S, Lim S, Novotny-Diermayr V.
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
Vaccine, 32(39):5041-8, 2014 Jegerlehner, A, Zabel, F, Langer, A, Dietmeier, K, Jennings, GT, Saudan, P, Bachmann, MF
Bacterially produced recombinant influenza vaccines based on virus-like particles.
PLoS One, Vol. 8(11) pp. e78947, 2013 Skibinski, DA, Hanson, BJ, Lin, Y, von Messling, V, Jegerlehner, A, Tee, JB, Chye, de H, Wong, SK, Ng, AA, Lee, HY, Au, B, Lee, BT, Santoso, L, Poidinger, M, Fairhurst, AM, Matter, A, Bachmann, MF, Saudan, P, Connolly,
JE Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine.
PLoS One, Vol. 8(10) pp. e76571, 2013 Saudan, P, Bachmann,
MF Noninfectious disease vaccines.
Vaccines 6th Ed., Plotkin, SA, Orenstein, W and Offit, PA (Eds.) Chapter 54, 2012 Schmitz, N, Beerli, RR, Bauer, M, Jegerlehner, A, Dietmeier, K, Maudrich, M, Pumpens, P, Saudan, P, Bachmann, MF.
Universal vaccine against influenza virus: Linking TLR signaling to anti-viral protection.
Eur J Immunol, Vol. 42(4) pp. 863-9, 2012 Wiessner, C, Wiederhold, KH, Tissot, AC, Frey, P, Danner, S, Jacobson, LH, Jennings, GT, Lüönd, R, Ortmann, R, Reichwald, J, Zurini, M, Mir, A, Bachmann, MF, Staufenbiel, M
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.
J Neurosci, Vol. 31(25) pp. 9323-31, 2011 Bachmann, MF, Jennings, GT.
Therapeutic vaccines for chronic diseases: successes and technical challenges.
Philos Trans R Soc Lond B Biol Sci, Vol. 366(1579) pp. 2815-22, 2011. Bachmann, MF, Jennings, GT.
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.
Nat Rev Immunol, Vol. 10(11) pp. 787-96, 2010 Zou, Y, Sonderegger, I, Lipowsky, G, Jennings, GT, Schmitz, N, Landi, M, Kopf, M, Bachmann, MF
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice.
Vaccine, Vol. 28(18) pp. 3192-200, 2010 Link, A, Bachmann, MF.
Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.
Immunotherapy, Vol. 2(4) pp. 561-74, 2010 Jennings, GT, Bachmann, MF
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases.
Annu Rev Pharmacol Toxicol, Vol. 49 pp. 303-26, 2009 Schmitz, N, Dietmeier, K, Bauer, M, Maudrich, M, Utzinger, S, Muntwiler, S, Saudan, P, Bachmann, MF
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy.
J Exp Med, Vol. 206(9) pp.1941-55, 2009 Tissot, AC, Maurer, P, Nussberger, J, Sabat, R, Pfister, T, Ignatenko, S, Volk, HD, Stocker, H, Müller, P, Jennings, GT, Wagner, F, Bachmann, MF
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
Lancet, Vol. 371(9615) pp. 821-7, 2008 Jennings, GT, Bachmann, MF.
The coming of age of virus-like particle vaccines.
 Vol. 389(5) pp. 521-36, 2008 Spohn, G, Keller, I, Beck, M, Grest, P, Jennings, GT, Bachmann, MF
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis.
Eur J Immunol, Vol. 38(3) pp. 877-87, 2008 Maurer, P, Bachmann, MF
Vaccination against nicotine: an emerging therapy for tobacco dependence.
Expert Opin Investig Drugs, Vol. 16(11) pp. 1775-83, 2007 Sonderegger, I, Röhn, TA, Kurrer, MO, Iezzi, G, Zou, Y, Kastelein, RA, Bachmann, MF, Kopf, M
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.
Eur J Immunol, Vol. 36(11) pp. 2849-56, 2006 Röhn, TA, Jennings, GT, Hernandez, M, Grest, P, Beck, M, Zou, Y, Kopf, M, Bachmann, MF
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.
Eur J Immunol, Vol. 36(11) pp. 2857-67, 2006